SRPT earnings analysis
What we found in SRPT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sarepta Therapeutics reported Q1 2026 revenues of $730.8M, down 2% QoQ, with a significant increase in net income to $331.0M compared to a loss of $447.5M in Q1 2025. The decrease in revenues stemmed largely from a 46% drop in sales of their ELEVIDYS product after safety concerns and regulatory actions impacted sales dynamics. Despite these challenges, management expressed optimism in the restructuring efforts and potential future collaborations in the developmental pipeline for targeted therapies.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenues Remain Robust Despite Decrease
- Total revenues for Q1 2026 were $730.8 million, only a 2% decrease from $744.9 million in Q4 2025.
- Significant Net Income Turnaround
- Net income for Q1 2026 was $331 million, a stark improvement from a loss of $447.5 million in Q1 2025.
- R&D Expenses Plummet by 80%
- Research and development expenses fell sharply to $154 million from $773.4 million in the previous year due to the restructuring initiatives.
- Strong Collaboration Revenue
- Collaboration and other revenues surged to $400.3 million, up from $133.3 million in the prior year, linked primarily to the Roche collaboration.
- Operating Income Surged
- Operating income improved to $358.4 million compared to an operating loss of $300.4 million in Q1 2025.
- Cash Position Remains High
- As of March 31, 2026, Sarepta maintained $748 million in cash and equivalents, a buffer for operational stability.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- ELEVIDYS Sales Plummeted
- Sales of ELEVIDYS fell 73% to $102 million from $375 million YoY due to safety concerns and regulatory hold.
- High Operating Expenses
- Selling, general and administrative costs decreased but still contributed $109 million in expenses which could pressure margins.
- Regulatory Scrutiny and Ongoing Litigation
- Sarepta faces significant legal challenges, including a securities class action lawsuit related to safety disclosures, which may result in financial penalties.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $2.88
- Operating margin
- 49.0%
- Segment
- PMO Products
- Segment
- ELEVIDYS
What they said about what is next.
Management's outlook indicates a focus on cost control and potential collaborations, but specific numeric guidance is not provided.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 2, 2026
- Sarepta recorded product sales-driven net revenues of $1,864.3 million in 2025, up from $1,788.0 million in 2024 and $1,144.9 million in 2023. The company is executing a July 2025 strategic restructuring to reduce…
- 10-Q · August 6, 2025
- Sarepta reported a strong Q2 with total revenues of $611,091,000 and diluted EPS of $1.89, driven by product sales ($513,123,000) and a step-up in collaboration revenue. Operating income swung to $115,577,000 from an…
- 10-Q · May 6, 2025
- Sarepta Therapeutics reported a disappointing Q1 2025, with revenue of $744.9 million, exceeding consensus but incurring significant loses resulting in an EPS of -4.60, far below analyst expectations. Management pointed…
- 10-Q · November 6, 2024
- Sarepta reported Q3 total revenue of $467,172,000, up $135,355,000 (40.8%) versus $331,817,000 in Q3 2023, driven by product sales and higher collaboration revenue. Operating income turned positive to $22,196,000 (4.8%…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SRPT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever